SPOTLIGHT: GPC finds positive satraplatin data

Researchers at GPC Biotech say that they've discovered that a group of patients previously treated with Taxotere demonstrated a positive trend toward survival when treated with the experimental prostate cancer drug satraplatin. That data has persuaded the company to continue research on the therapy, which failed a pivotal late-stage trial. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.